share_log
Breakings ·  02:29

JPMorgan Securities Co., Ltd. has upgraded the rating of WUXI BIO to overweight, with Analyst Yang Huang's previous rating being neutral. The Target Price is 20 HKD, which is expected to rise by 24% compared to the latest closing price.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment